WHO: Indian strain of COVID-19 resistant to antibodies
Mutations of the Indian strain of COVID-19 indicate its high infectivity and resistance to antibodies in both those who have been ill and vaccinated, the World Health Organization reported.
New varieties of the virus have been discovered in India, including B.1.617. It is a variant with mutations E484Q and L452R that was first identified in India from samples collected on December 1, 2020.
According to preliminary research results, the L452R mutation may interfere with the effectiveness of certain monoclonal antibody treatments. E484Q can neutralize antibodies. Thus, the antibodies that have appeared in a person who has recovered from COVID-19 will not help in the fight against Indian mutations.
Moreover, the new strain is also thought to be highly virulent, which means it is more likely to infect and cause disease.
WHO experts have not yet figured out what influenced the virus mutations in India. One of the factors could be the holding of mass events that increased its spread, as well as the mitigation of antiquated measures in the country.




















EBRD to Launch AMD 5 Billion Floating-Rate Bond Offering in Armenia
IDBank warns of scam calls impersonating pension funds
The Power of One Dram and the Armenian State Symphony Orchestra Conclude the Forest Project Launched...
Idram is the general partner of the "Towards Conscious Parenting 2026" annual conference
From Financial Adventures to Great Victories: The 4th Junius Financial Online Tournament Wrapped Up
Converse Bank Completes the Placement of EBRD Bonds
Polytechnic University Graduation Ceremony Held with the Support of Unibank
A little corner of France in Hrazdan, with the partnership of Converse SME